LIVIVO - Search results -

Search results

Result 1 - 10 of total 19

Search options

Article ; Online: Case/noncase analysis of the FDA Adverse Events Reporting System suggests higher reporting odds of photosensitivity and esophageal symptoms for sarecycline than of those for other tetracyclines.

Jedlowski, Patrick M / Jedlowski, Mahdieh F

Journal of the American Academy of Dermatology

2022 Volume 87, Issue 5, Page(s) 1150–1153

MeSH term(s)	Adverse Drug Reaction Reporting Systems ; Anti-Bacterial Agents/adverse effects ; Humans ; Tetracyclines/adverse effects ; United States/epidemiology ; United States Food and Drug Administration
Chemical Substances	Anti-Bacterial Agents ; Tetracyclines ; sarecycline (94O110CX2E)
Language	English
Publishing date	2022-02-19
Publishing country	United States
Document type	Journal Article
ZDB-ID	603641-7
ISSN	1097-6787 ; 0190-9622
ISSN (online)	1097-6787
ISSN	0190-9622
DOI	10.1016/j.jaad.2022.02.025
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1540: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Use of fractionated laser therapy for the treatment of androgenetic alopecia: a systematic review and meta-analysis.

Jedlowski, Patrick M / Anthony, Michelle

Lasers in medical science

2023 Volume 39, Issue 1, Page(s) 4

Abstract: Procedural management, including fractionated laser therapy, has been increasingly investigated for the management of androgenetic alopecia (AGA). However, no comprehensive resources exist detailing the efficacy of fractionated laser therapies used for ... ...

Abstract	Procedural management, including fractionated laser therapy, has been increasingly investigated for the management of androgenetic alopecia (AGA). However, no comprehensive resources exist detailing the efficacy of fractionated laser therapies used for the treatment of AGA. A systematic review investigating fractionated laser use for AGA was performed, separated into each distinct fractionated laser modality. A meta-analysis was performed to examine improvement in hair counts and hair shaft diameter. Fourteen studies were included for systematic review, which identified the use of erbium-glass, thulium, erbium-ytrrium:aluminum garnet (YAG), and carbon dioxide (CO
MeSH term(s)	Humans ; Erbium ; Thulium ; Alopecia/radiotherapy ; Alopecia/surgery ; Hair ; Laser Therapy ; Treatment Outcome
Chemical Substances	Erbium (77B218D3YE) ; Thulium (8RKC5ATI4P)
Language	English
Publishing date	2023-12-13
Publishing country	England
Document type	Meta-Analysis ; Systematic Review ; Journal Article ; Review
ZDB-ID	632808-8
ISSN	1435-604X ; 0268-8921
ISSN (online)	1435-604X
ISSN	0268-8921
DOI	10.1007/s10103-023-03946-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2148: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Morbilliform rash after administration of Pfizer-BioNTech COVID-19 mRNA vaccine.

Jedlowski, Patrick M / Jedlowski, Mahdieh F

Dermatology online journal

2021 Volume 27, Issue 1

MeSH term(s)	Adult ; COVID-19/prevention & control ; COVID-19 Vaccines/adverse effects ; Drug Eruptions/etiology ; Health Personnel ; Humans ; Male ; Recurrence ; SARS-CoV-2
Chemical Substances	COVID-19 Vaccines ; BNT162 vaccine (N38TVC63NU)
Language	English
Publishing date	2021-01-15
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	2026239-5
ISSN	1087-2108 ; 1087-2108
ISSN (online)	1087-2108
ISSN	1087-2108
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Coronavirus disease 2019-associated immunoglobulin A vasculitis/Henoch-Schönlein purpura: A case report and review.

Jedlowski, Patrick M / Jedlowski, Mahdieh F

The Journal of dermatology

2021 Volume 49, Issue 1, Page(s) 190–196

Abstract: Immunoglobulin A (IgA) vasculitis or Henoch-Schönlein purpura is a predominantly pediatric disease occurring after a triggering viral or bacterial infection. Conversely, drug exposure is the most common inciting event in adult cases of IgA vasculitis. ... ...

Abstract	Immunoglobulin A (IgA) vasculitis or Henoch-Schönlein purpura is a predominantly pediatric disease occurring after a triggering viral or bacterial infection. Conversely, drug exposure is the most common inciting event in adult cases of IgA vasculitis. Recently, data has suggested a temporal association between coronavirus disease 2019 (COVID-19) and the development of IgA vasculitis in children and adults. Here, we describe a case of IgA vasculitis with nephritis in a 70-year-old man with COVID-19 and perform a comprehensive review of eight reported cases of suspected COVID-19-associated IgA vasculitis. When compared to classical IgA vasculitis, COVID-19-associated IgA vasculitis exclusively affects males (p < 0.00002) and is more common in adults (p < 0.005). Among cases of COVID-19-associated IgA vasculitis, adult cases were associated with significantly more arthralgia than pediatric cases (p = 0.04). In cases where skin biopsy was obtained, direct immunofluorescence (DIF) was negative for IgA in 50% of cases; thereafter, kidney biopsy DIF was positive for IgA in all cases. With this study, we provide support for an association between IgA vasculitis and severe acute respiratory syndrome coronavirus 2 infection and provide clinical information differentiating its manifestations from classical IgA vasculitis.
MeSH term(s)	Adult ; Aged ; COVID-19 ; Child ; Humans ; IgA Vasculitis/complications ; IgA Vasculitis/diagnosis ; Immunoglobulin A ; Male ; SARS-CoV-2 ; Skin
Chemical Substances	Immunoglobulin A
Language	English
Publishing date	2021-11-05
Publishing country	England
Document type	Case Reports ; Journal Article ; Review
ZDB-ID	800103-0
ISSN	1346-8138 ; 0385-2407
ISSN (online)	1346-8138
ISSN	0385-2407
DOI	10.1111/1346-8138.16211
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.B 1950: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Medications affecting the insulin-like growth factor 1/growth hormone axis, including teprotumumab, somatostatin analogs, and anti-calcitonin gene-related peptide monoclonal antibodies, are associated with elevated reporting odds of alopecia in women: A pharmacovigilance study.

Jedlowski, Patrick Michael / Jedlowski, Mahdieh F / Fazel, Mohammad

Journal of the American Academy of Dermatology

2023 Volume 89, Issue 2, Page(s) 408–410

MeSH term(s)	Female ; Humans ; Somatostatin/metabolism ; Calcitonin Gene-Related Peptide/metabolism ; Insulin-Like Growth Factor I ; Pharmacovigilance ; Antibodies, Monoclonal, Humanized ; Growth Hormone ; Alopecia/chemically induced
Chemical Substances	Somatostatin (51110-01-1) ; Calcitonin Gene-Related Peptide (JHB2QIZ69Z) ; teprotumumab (Y64GQ0KC0A) ; Insulin-Like Growth Factor I (67763-96-6) ; Antibodies, Monoclonal, Humanized ; Growth Hormone (9002-72-6)
Language	English
Publishing date	2023-04-15
Publishing country	United States
Document type	Journal Article
ZDB-ID	603641-7
ISSN	1097-6787 ; 0190-9622
ISSN (online)	1097-6787
ISSN	0190-9622
DOI	10.1016/j.jaad.2023.03.057
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1540: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Annular plaques and nodules at vaccination sites in an infant.

Jedlowski, Patrick M / Davis, Tracy L / Wolter, Sierra C

Pediatric dermatology

2023 Volume 40, Issue 6, Page(s) 1127–1129

MeSH term(s)	Humans ; Infant ; Vaccination/adverse effects ; Drug Eruptions
Language	English
Publishing date	2023-04-20
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	605539-4
ISSN	1525-1470 ; 0736-8046
ISSN (online)	1525-1470
ISSN	0736-8046
DOI	10.1111/pde.15328
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1882: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Multiple myeloma, haematologic malignancy and immunosuppressant and immunomodulatory medications are associated with sebaceous carcinoma, a pharmacovigilance study of the FDA adverse event reporting system.

Jedlowski, Patrick M / DuPont, Jason P

Journal of the European Academy of Dermatology and Venereology : JEADV

2023 Volume 38, Issue 5, Page(s) 937–944

Abstract: Background: Sebaceous carcinoma (SC) is a rare skin cancer with significant associated morbidity and mortality. A known association exists between immunosuppression, in particular solid organ transplant patients (SOTR), and SC. However, the comparative ... ...

Abstract	Background: Sebaceous carcinoma (SC) is a rare skin cancer with significant associated morbidity and mortality. A known association exists between immunosuppression, in particular solid organ transplant patients (SOTR), and SC. However, the comparative reporting odds ratios (ROR) of different immunosuppressive medications and SC are incompletely defined. Objectives: To examine the relationship between SC and medication exposure in the FDA adverse event reporting system (FAERS). Methods: Case-control analyses were performed in FAERS from 1968 to 2021 to examine the reporting odds ratios (ROR) for SC. Results: A total of 58 medication-associated SC cases were identified. Immunosuppressant medication exposure was noted in 81% cases, with 20% total cases occurring in SOTR. Medications affecting the TNF- α -IL-1-IL-2-IL-6 inflammatory axis were associated with elevated ROR for SC, including thalidomide (ROR 22.63, 95% CI 5.52-92.72), lenalidomide (ROR 10.86, 95% CI 4.93-23.94), cyclosporine, tacrolimus, tocilizumab, tofacitinib and ruxolitinib. Thirty per cent of cases of SC occurred with an associated haematologic malignancy or dyscrasia, including chronic lymphocytic leukaemia, non-Hodgkin lymphoma and multiple myeloma. Conclusions: SC is associated with exposure to immunosuppressive medications, especially in SOTR patients. A significant portion of cases with SC had an associated haematology malignancy, in particular multiple myeloma with exposure to lenalidomide.
MeSH term(s)	Humans ; United States ; Multiple Myeloma/drug therapy ; Male ; Female ; Adverse Drug Reaction Reporting Systems ; Middle Aged ; Immunosuppressive Agents/adverse effects ; Immunosuppressive Agents/therapeutic use ; Aged ; United States Food and Drug Administration ; Pharmacovigilance ; Case-Control Studies ; Hematologic Neoplasms/drug therapy ; Sebaceous Gland Neoplasms/chemically induced ; Immunologic Factors/adverse effects ; Thalidomide/adverse effects ; Adult ; Lenalidomide/adverse effects ; Pyrazoles/adverse effects ; Pyrimidines/adverse effects ; Tacrolimus/adverse effects ; Tacrolimus/therapeutic use ; Aged, 80 and over ; Nitriles
Chemical Substances	Immunosuppressive Agents ; Immunologic Factors ; Thalidomide (4Z8R6ORS6L) ; Lenalidomide (F0P408N6V4) ; ruxolitinib (82S8X8XX8H) ; Pyrazoles ; Pyrimidines ; Tacrolimus (WM0HAQ4WNM) ; Nitriles
Language	English
Publishing date	2023-12-10
Publishing country	England
Document type	Journal Article
ZDB-ID	1128828-0
ISSN	1468-3083 ; 0926-9959
ISSN (online)	1468-3083
ISSN	0926-9959
DOI	10.1111/jdv.19703
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3492: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 413: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020.

Jedlowski, Patrick M / Jedlowski, Mahdieh F / Fazel, Maryam T

American journal of clinical dermatology

2021 Volume 22, Issue 6, Page(s) 891–900

Abstract: Background: In recent years, an association between dipeptidyl peptidase-4 (DPP-4) inhibitors and bullous pemphigoid has been detected in pharmacovigilance studies in European and Asian countries; however, no pharmacovigilance data have been published ... ...

Abstract	Background: In recent years, an association between dipeptidyl peptidase-4 (DPP-4) inhibitors and bullous pemphigoid has been detected in pharmacovigilance studies in European and Asian countries; however, no pharmacovigilance data have been published yet in the USA. Objective: The objective of this study was to examine the relationship between bullous pemphigoid and DPP-4 inhibitors and other oral diabetes mellitus medications in the FDA Adverse Event Reporting System (FAERS). Methods: Case/non-case analyses were performed in the FAERS using data from 2006 to 2020 to examine the reporting odds ratio (ROR) signal for bullous pemphigoid for all classes of oral diabetes medications. These analyses were performed under multiple conditions to control for bias: (1) comparison to all other drugs in the FAERS; (2) comparison to other diabetes medications; and (3) comparison to all other diabetes medications where only a single agent was implicated. Results: A statistically significant ROR for bullous pemphigoid was found for DPP-4 inhibitors under all conditions: (1) 109.79 (95% confidence interval [CI] 101.61-118.62); (2) 74.46 (95% CI 60.58-91.52); and (3) 35.94 (95% CI 27.91-46.28). A larger signal was seen for non-US Food and Drug Administration (FDA)-approved (anagliptin, vildagliptin, teneligliptin) vs FDA-approved DPP-4 inhibitors (alogliptin, linagliptin, saxagliptin, sitagliptin), likely because of an overestimation of the ROR for non-FDA-approved drugs. The largest signal was seen under conditions 1 and 2 with vildagliptin (1) 1022.83 (95% CI 909.45-1150.35) and (2) 158.84 (95% CI 127.01-198.66) followed by anagliptin (1) 628.63 (95% CI 221.36-1785.24) and (2) 60.64 (95% CI 20.98-175.26), alogliptin, teneligliptin, linagliptin, sitagliptin, and saxagliptin. Under condition 3, the largest signal was seen with linagliptin 122.25 (95% CI 93.96-159.07). Both metformin and the sulfonylureas had a significant ROR under condition 2 [3.42 (95% CI 3.01-3.89) and 2.07 (95% CI 1.66-2.57) respectively]; however, this association was not present under condition 3 as only confounded cases occurred, and a large majority of reported cases had concurrent exposure to a DPP-4 inhibitor. Conclusions: Our findings support an association between DPP-4 inhibitors and bullous pemphigoid. This association was maintained under controls to limit bias and falsely elevated signal, including controlling for disease state and cases with multiple drug exposures. Non-FDA-approved DPP-4 inhibitors had a larger ROR compared with FDA-approved DPP-4 inhibitors, likely owing to fewer reported adverse effects overall for non-FDA-approved drugs in FAERS.
MeSH term(s)	Administration, Oral ; Adverse Drug Reaction Reporting Systems/statistics & numerical data ; Diabetes Mellitus/drug therapy ; Dipeptidyl-Peptidase IV Inhibitors/administration & dosage ; Dipeptidyl-Peptidase IV Inhibitors/adverse effects ; Humans ; Pemphigoid, Bullous/chemically induced ; Pemphigoid, Bullous/epidemiology ; Pemphigoid, Bullous/immunology ; Pharmacovigilance ; United States ; United States Food and Drug Administration/statistics & numerical data
Chemical Substances	Dipeptidyl-Peptidase IV Inhibitors
Language	English
Publishing date	2021-07-21
Publishing country	New Zealand
Document type	Journal Article
ZDB-ID	1502476-3
ISSN	1179-1888 ; 1175-0561
ISSN (online)	1179-1888
ISSN	1175-0561
DOI	10.1007/s40257-021-00625-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5639: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Polydactylous Squamous Cell Carcinoma of the Nail Unit: A Structured Review of the Literature.

Jedlowski, Patrick M / Jedlowski, Mahdieh F / Segal, Robert J

Journal of cutaneous medicine and surgery

2020 Volume 25, Issue 3, Page(s) 303–314

Abstract: Squamous cell carcinoma of the nail unit (SCCNU) is a rare neoplastic condition that involves multiple digits (polydactylous SCCNU) in only 3.9% of cases. Here, we report a case of polydactylous SCCNU and perform a comprehensive review of MEDLINE and ... ...

Abstract	Squamous cell carcinoma of the nail unit (SCCNU) is a rare neoplastic condition that involves multiple digits (polydactylous SCCNU) in only 3.9% of cases. Here, we report a case of polydactylous SCCNU and perform a comprehensive review of MEDLINE and Embase to collate 44 cases of polydactylous SCCNU reported to date. Polydactylous patients were younger on average (48 to 61-63 years) and had a longer diagnostic delay (44 vs 35.1 months) compared with reported monodactylous cases. Human papillomavirus (HPV) positivity was observed in 49% of cases, and the most common serotypes noted were 16 (25.8%), 73 (16.1%), 58 (9.7%), 18 (6.5%), and 33 (6.5%). Twenty percent of the cases were in immunosuppressed individuals who had a statistically significant lower age at diagnosis (39.33 years vs 51.12 years;
MeSH term(s)	Age Factors ; Carcinoma, Squamous Cell/diagnosis ; Carcinoma, Squamous Cell/etiology ; Carcinoma, Squamous Cell/immunology ; Carcinoma, Squamous Cell/virology ; Humans ; Nail Diseases/diagnosis ; Nail Diseases/etiology ; Nail Diseases/immunology ; Nail Diseases/virology ; Risk Factors ; Skin Neoplasms/diagnosis ; Skin Neoplasms/etiology ; Skin Neoplasms/immunology ; Skin Neoplasms/virology
Language	English
Publishing date	2020-11-30
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1361720-5
ISSN	1615-7109 ; 1203-4754
ISSN (online)	1615-7109
ISSN	1203-4754
DOI	10.1177/1203475420977474
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4987: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Severe Myositis, Myocarditis, and Myasthenia Gravis with Elevated Anti-Striated Muscle Antibody following Single Dose of Ipilimumab-Nivolumab Therapy in a Patient with Metastatic Melanoma.

Fazel, Mahdieh / Jedlowski, Patrick M

Case reports in immunology

2019 Volume 2019, Page(s) 2539493

Abstract: Immune checkpoint inhibitors targeting programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 have improved survival in patients with metastatic melanoma, especially in combination (i.e., ipilimumab-nivolumab). Postmarketing ... ...

Abstract	Immune checkpoint inhibitors targeting programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 have improved survival in patients with metastatic melanoma, especially in combination (i.e., ipilimumab-nivolumab). Postmarketing surveillance has identified rare but at times life-threatening adverse effects associated with these agents in combination and as monotherapy, which include myocarditis, myositis, myasthenia gravis (MG), and hepatotoxicity. Further evaluation of immune checkpoint therapy-induced MG identified the rapid clinical progression, prolonged treatment/supportive therapy course, and higher frequency of myasthenic crisis in these patients versus those with idiopathic MG. More rapid incorporation of aggressive treatment options (i.e., intravenous immunoglobulin, plasmapheresis) may be necessary in these cases. Anti-striational antibodies are often detected in individuals with myasthenia gravis and concurrent myositis and myocarditis. A high-index of suspicion is necessary to assist with rapid treatment initiation as these patients can rapidly deteriorate into respiratory compromise. A case of a 78-year-old woman with metastatic melanoma status after combination therapy with ipilimumab-nivolumab that developed transaminitis, myositis, myocarditis, and myasthenia gravis (with positive anti-striational antibodies) five days after the first cycle, is presented. Despite high dose intravenous methylprednisolone and intravenous immunoglobulin treatment, she ultimately entered hospice care eight days after hospital admission, 36 days after her first cycle.
Language	English
Publishing date	2019-04-30
Publishing country	Egypt
Document type	Case Reports
ZDB-ID	2695564-7
ISSN	2090-6617 ; 2090-6609
ISSN (online)	2090-6617
ISSN	2090-6609
DOI	10.1155/2019/2539493
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito